Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa

被引:18
|
作者
Cheng, Chih-Yuan [1 ,2 ,3 ]
Quaife, Matthew [1 ]
Eakle, Robyn [4 ]
Escobar, Maria A. Cabrera [4 ]
Vickerman, Peter [5 ]
Terris-Prestholt, Fern [1 ]
机构
[1] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, 15-17 Tavistock Pl, London WC1H 9SH, England
[2] Heidelberg Univ, Med Fac Mannheim, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany
[3] German Canc Res Ctr, Div Hlth Econ, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
[4] Univ Witwatersrand, Wits RHI, 22 Esselen St, ZA-2001 Johannesburg, South Africa
[5] Univ Bristol, Sch Social & Community Med, Canynge Hall,39 Whatley Rd, Bristol BS8 2PS, Avon, England
基金
英国经济与社会研究理事会;
关键词
HIV prevention; Long-acting injectable pre-exposure prophylaxis; Heterosexual men; South Africa; Biomedical strategies; ANTIRETROVIRAL PROPHYLAXIS; PREVENTION; INFECTION; SEX; RISK; PREFERENCES; TRANSMISSION; WILLINGNESS; PERCEPTIONS; TENOFOVIR;
D O I
10.1186/s12889-019-7276-1
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BackgroundHeterosexual men in South Africa are a large key population to exposure to HIV, yet preferences for HIV pre-exposure prophylaxis (PrEP) among this population have not, to date, been investigated in the literature. This paper aims to explore HIV prevention preferences among heterosexual men in urban South Africa, as well as to examine the demand and characteristics of men who favour long-acting injectable (LAI) PrEP over condoms and oral PrEP.MethodsData were collected among 178 self-reported HIV-negative heterosexual men, who were given example products and information before being asked which they preferred. Multivariate logistic regression was used to analyse which characteristics were associated with product choice.Results48% (n=85) of participants preferred LAI PrEP, while 33% (n=58) and 20% (n=35) chose oral PrEP and condoms respectively. Having children (marginal effect=0.22; 95% CI [0.01, 0.44]) or having higher risk attitude scores (marginal effect=0.03; 95% CI [0.01, 0.06]) was significantly associated with a choice of LAI PrEP, while those who had unprotected anal intercourse (marginal effect=-0.42; 95% CI [-0.57, -0.27]) and those who were concerned with protection against other sexually transmitted infections over HIV (marginal effect=-0.42; 95% CI [-0.60, -0.24]) appeared less likely to prefer LAI PrEP.ConclusionsThe results suggested a relatively high demand and theoretical acceptability for LAI PrEP among heterosexual men in urban South Africa, but there appeared to be fewer distinct predictors for the willingness to use LAI PrEP compared to studies conducted among gay and bisexual men and women. Nevertheless, the findings contribute to the mapping of the demand and determinants of heterosexual men's preferences for novel antiretroviral-based prevention in sub-Saharan Africa, and the data could aid in the differentiated design of future HIV prevention strategies using LAI PrEP in conjunction with other methods.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] New challenges for HIV testing in the setting of long-acting cabotegravir pre-exposure prophylaxis
    Williams, Eloise
    Chibo, Doris
    D'Costa, Jodie
    Nicholson, Suellen
    Jackson, Kathy
    Lim, Chuan K.
    Williamson, Deborah A.
    PATHOLOGY, 2025, 57 (01)
  • [32] Tenofovir alafenamide fumarate loaded long-acting microsphere for HIV pre-exposure prophylaxis
    Pawar, Manoj A.
    Abadi, Leila Fotooh
    Rojekar, Satish, V
    Yawalkar, Ankita N.
    Kulkarni, Smita S.
    Vavia, Pradeep R.
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2023, 87
  • [33] Statistical approaches to accelerate the development of long-acting antiretrovirals for HIV pre-exposure prophylaxis
    Glidden, David V.
    CURRENT OPINION IN HIV AND AIDS, 2020, 15 (01) : 56 - 60
  • [34] Conjoint Analysis of User Acceptability of Sustained Long-Acting Pre-Exposure Prophylaxis for HIV
    Schieffer, Robert J.
    Bryndza Tfaily, Ewa
    D'Aquila, Richard
    Greene, George J.
    Carballo-Dieguez, Alex
    Giguere, Rebecca
    Tagliaferri Rael, Christine
    Kiser, Patrick F.
    Hope, Thomas J.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2022, 38 (04) : 336 - 345
  • [35] HIV pre-exposure prophylaxis (PrEP) uptake among alcohol users in rural South Africa
    Grammatico, M.
    Moll, A.
    Choi, K.
    Springer, S.
    Shenoi, S.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24
  • [36] Assessing Preferences for Long-Acting Injectable Pre-Exposure Prophylaxis Among Young Adult Sexual Minority Men and Transgender Women
    Weeden, Terrance
    Garofalo, Robert
    Johnson, Amy K.
    Schnall, Rebecca
    Scherr, Thomas
    Kuhns, Lisa M.
    Cervantes, Marbella
    ACADEMIC PEDIATRICS, 2024, 24 (07) : 1110 - 1115
  • [37] Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17-24 years old
    John, Steven A.
    Zapata, Juan P.
    Dang, Madeline
    Pleuhs, Benedikt
    O'Neil, Andrew
    Hirshfield, Sabina
    Walsh, Jennifer L.
    Petroll, Andrew E.
    Quinn, Katherine G.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [38] Men's voices on LA_PrEP: The acceptability and preferences of Long acting Pre-Exposure Prophylaxis (LA-PrEP) among Cis-gender men and Men who have sex with men in South Africa
    Atujuna, M.
    Duby, Z.
    Minnis, A.
    Palanee-Phillips, T.
    Tenza, S.
    Reddy, K.
    Nkomana, N.
    Bekker, L. -G.
    Montgomery, E.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 177 - 177
  • [39] Cost-effectiveness and public-health impact of cabotegravir long-acting injectable for HIV pre-exposure prophylaxis in Canada
    Adelakun, Adenike
    Dolph, Michael
    Matthews, Emily
    Oglesby, Alan
    Campbell, Kelly
    Davis, Ashley
    Xu, Janine
    Hardy, Isabelle
    Danchenko, Natalya
    Anderson, Sarah-Jane
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 234 - 235
  • [40] Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre-Exposure Prophylaxis Among Women Who Inject Drugs
    Roth, Alexis M.
    Bartholomew, Tyler S.
    Ward, Kathleen M.
    Groves, Allison
    Mazzella, Silvana
    Bellamy, Scarlett
    Amico, K. Rivet
    Carrico, Adam W.
    Ironson, Gail
    Krakower, Douglas
    CLINICAL INFECTIOUS DISEASES, 2024,